Acrux Limited

ACR

AU000000ACR3

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 06:59:49 16/07/2024 BST			5-day change	1st Jan Change
0.066 ^AUD	+6.45%		+10.00%	+50.00%

06-28	Acrux Secures AU$1.5 Million Funding Facility; Shares Fall 3%	MT
06-17	Percheron Therapeutics Appoints CFO	MT

Acrux Limited : Lilly comments on Axiron at JP Morgan Healthcare Conference

January 13, 2012 at 12:32 am

MarketScreener.com By

ACRUX (ACR) - ASX ANNOUNCEMENT 13 JANUARY 2012

LILLY COMMENTS ON AXIRON AT JP MORGAN HEALTHCARE CONFERENCE

Acrux (ASX: ACR) today reported that John Lechleiter, Chairman, President and CEO of Eli Lilly & Company included comments on Axiron in a presentation at the JP Morgan Healthcare Conference in San Francisco. During the presentation, Dr Lechleiter commented "We've been pleased with the uptake of Axiron since it was launched last spring. The most recent IMS data show we've achieved 10% share of market in total prescriptions and that over one in five new patient starts are going to Axiron."

Contact

Richard Treagus, CEO: 0417 520 509

About Acrux www.acrux.com.au

Latest news about Acrux Limited

Acrux Secures AU$1.5 Million Funding Facility; Shares Fall 3%	06-28	MT
Percheron Therapeutics Appoints CFO	06-17	MT
Acrux, TruPharma Launch Dapsone 5% Gel in US	04-03	MT
Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024	02-28
Acrux Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
Acrux Gets AU$3 Million Tax Rebate for Fiscal Year 2023	11-08	MT
Transcript : Acrux Limited, 2023 Earnings Call, Aug 31, 2023	31/08/23
Acrux Limited Reports Earnings Results for the Full Year Ended June 30, 2023	24/08/23	CI
Acrux Files US FDA Application for Generic Topical Medication; Shares Jump 7%	04/07/23	MT
Australian Shares Retreat Anew on Rate Hike, Slower-than-Expected GDP Growth	07/06/23	MT
Acrux Secures US FDA Approval for Generic Version of Topical Drug	07/06/23	MT
Acrux Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23/02/23	CI
IT, Energy Stocks Push Australian Benchmark to Nine-Month High	23/01/23	MT
Acrux Selling Lenzetto Royalties for AU$6.4 Million	23/01/23	MT
Acrux Announces Gedeon Richter Buyout of Future Lenzetto Royalties for EUR 4.1 Million	22/01/23	CI
Acrux Gets Favorable Outcome in US FDA Assessment	19/01/23	MT
Higher Oil, Gold Prices Send Australian Shares Back to Positive Territory	21/12/22	MT
Acrux Launches Generic Topical Anesthesia Cream in the US; Shares Jump 7%	21/12/22	MT
Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States	20/12/22	CI
Acrux, Amring Pharmaceuticals Terminate Co-Development Deal for Generic Topical Product for US Market	15/12/22	MT
Acrux Limited and Amring Pharmaceuticals Inc. Announce Mutual Termination of Co-Development Agreement	15/12/22	CI
Australian Tax Office Grants Overseas Finding Claim for Acrux Subsidiary	03/11/22	MT
Acrux Receives $1.5 Million R&D Tax Rebate	03/10/22	MT
Acrux Gets R&D Tax Refund	26/09/22	MT
Acrux Limited Reports Earnings Results for the Full Year Ended June 30, 2022	26/08/22	CI

Chart Acrux Limited

Duration

Period

More charts

Company Profile

Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ACRUX LIMITED	+50.00%	12.22M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.54B
OTSUKA HOLDINGS CO., LTD.	+34.52%	24.51B
SANDOZ GROUP AG	+27.12%	16.48B
CIPLA LIMITED	+21.19%	14.66B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.3B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.84%	6.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+18.15%	5.87B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals

Acrux Limited

Equities

ACR

AU000000ACR3

Pharmaceuticals

Acrux Limited : Lilly comments on Axiron at JP Morgan Healthcare Conference

Latest news about Acrux Limited

Chart Acrux Limited

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Generic Pharmaceuticals